TD Cowen lowered the firm’s price target on NeoGenomics (NEO) to $12 from $17 and keeps a Buy rating on the shares. The firm had a sales miss and after also having a Q4 sales miss, its reiterated 2025 guidance appears aggressive.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: